Mice were intraperitoneally injected with VCR sulfate (0.1 mg/kg; Shenzhen Main Luck Pharmaceutical Incorporated, China; dissolved in normal saline) once a day for ve consecutive days (Shen et al. 2015) (link).
KN-93 (a CaMKII inhibitor, 70 nM, 10 µl; Selleck, Houston, USA; intrathecal), Gap27 (a synthetic Cx43 mimetic peptide; 14.4, 43.2, and 144 nM, 10 µl each; MedChemExpresswere, New Jersey, USA) and L -Ascorbic acid (a Cav3.2 channels inhibitor; 30, 100, and 300 µM, 10 µl each; Tocris Bioscience,, Bristol, UK; intrathecal) were administered into the dorsal subarachnoid space of animals daily for 2 consecutive days from day 6 after the rst-day vincristine injection. The control groups were injected with intrathecal dimethyl sulfoxide or saline.
Cx43-speci c small interfering RNA (siRNA) was provided by RiboBio (Guangzhou, China). Cx43 siRNA (50 nM, 10 µl) was dissolved in the transfection reagent riboFETC™ CP and intrathecally injected daily for 2 consecutive days from day 6 after the rst-day VCR injection. Missense siRNA was administered intrathecally in the same way as a sham treatment.
KN-93 (a CaMKII inhibitor, 70 nM, 10 µl; Selleck, Houston, USA; intrathecal), Gap27 (a synthetic Cx43 mimetic peptide; 14.4, 43.2, and 144 nM, 10 µl each; MedChemExpresswere, New Jersey, USA) and L -Ascorbic acid (a Cav3.2 channels inhibitor; 30, 100, and 300 µM, 10 µl each; Tocris Bioscience,, Bristol, UK; intrathecal) were administered into the dorsal subarachnoid space of animals daily for 2 consecutive days from day 6 after the rst-day vincristine injection. The control groups were injected with intrathecal dimethyl sulfoxide or saline.
Cx43-speci c small interfering RNA (siRNA) was provided by RiboBio (Guangzhou, China). Cx43 siRNA (50 nM, 10 µl) was dissolved in the transfection reagent riboFETC™ CP and intrathecally injected daily for 2 consecutive days from day 6 after the rst-day VCR injection. Missense siRNA was administered intrathecally in the same way as a sham treatment.